1. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

2. Activity Goals

3. Epidemiology: Ovarian Cancer

4. PARP and DNA Repair

5. BRCA and DNA Repair

6. Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency

7. PARP Inhibition in BRCA-like Solid Tumors

8. Repair Mechanisms and BRCAness

9. BRCA Testing: When Should it Be Done?

10. PARP Inhibition: Mechanism of Action

11. Clinical Outcomes in Patients With BRCA Mutations

12. PARP Inhibitors in Clinical Trials

13. Case Study 1

14. Treatment Options

15. Anticipated PFS With Standard Treatment

16. Olaparib as Maintenance Therapy: Study Design

17. Results of BRCA Testing

18. Results

19. ASCO 2014: Cediranib/Olaparib

20. PFS With Cediranib/Olaparib Superior to Olaparib Alone

21. PFS Increased With Cediranib/Olaparib Combination

22. Phase 2: PLD vs Olaparib

23. Case Study 2

24. Treatment Approach

25. Neoadjuvant Chemotherapy (NACT) vs Primary Debulking Surgery (PDS)

26. Dose-Dense Paclitaxel + Carboplatin vs Conventional Regimen

28. BRCAness and Response to Chemotherapy

29. GOG9923

30. Key Issues for Future Developments of PARP Inhibitors

31. Abbreviations

32. References

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)